| WB | 咨询技术 | Rat |
| IF | 1/20 | Rat |
| IHC | 咨询技术 | Rat |
| ICC | 技术咨询 | Rat |
| FCM | 咨询技术 | Rat |
| Elisa | 咨询技术 | Rat |
| Aliases | ASP2; Bace; C76936 |
| Entrez GeneID | 23821 |
| WB Predicted band size | Calculated MW: 56 kDa; Observed MW: 70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Rat |
| Immunogen | Recombinant protein of mouse BACE1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于BACE1抗体的3篇代表性文献的简化示例(注：文献信息为示例性概括，具体内容请参考实际论文)：
1. **文献名称**：*Selective targeting of BACE1 by monoclonal antibodies for Alzheimer's disease therapy*
**作者**：Yan R. et al.
**摘要**：该研究开发了一种特异性靶向BACE1的单克隆抗体，通过体外实验和小鼠模型证明其能有效抑制β-淀粉样蛋白(Aβ)的生成，且未显著影响其他蛋白酶活性，提示其治疗阿尔茨海默病的潜力。
2. **文献名称**：*A humanized anti-BACE1 antibody reduces amyloid-beta production in vivo*
**作者**：McConlogue L. et al.
**摘要**：研究者报道了一种人源化BACE1抗体，在转基因小鼠模型中证实其可穿透血脑屏障，降低脑内Aβ水平，并改善认知功能，为临床转化提供了实验支持。
3. **文献名称**：*Mechanism of BACE1 inhibition by antibodies binding to the active site*
**作者**：Zhou L. et al.
**摘要**：通过结构生物学分析，揭示了抗体通过结合BACE1活性位点阻断其与APP底物相互作用，从而抑制Aβ生成的分子机制，为优化抗体设计提供了理论依据。
如需具体文献，建议通过PubMed或Google Scholar检索关键词“BACE1 antibody therapeutic”或“BACE1 inhibitor”获取最新研究。
BACE1 (β-site amyloid precursor protein-cleaving enzyme 1), also known as beta-secretase 1. is a transmembrane aspartic protease critical in the production of amyloid-beta (Aβ) peptides. These peptides aggregate into plaques in the brain, a hallmark of Alzheimer’s disease (AD). Inhibiting BACE1 activity has been a major therapeutic strategy to reduce Aβ levels and slow AD progression. BACE1 antibodies, designed to selectively target and neutralize the enzyme, represent a promising approach in this context. Unlike small-molecule inhibitors, antibodies offer high specificity, potentially minimizing off-target effects. They may block BACE1’s active site, interfere with substrate binding, or promote its degradation via immune pathways.
Research on BACE1 antibodies has advanced in preclinical studies, demonstrating reduced Aβ levels in animal models. However, clinical translation faces challenges, including limited blood-brain barrier penetration and uncertainties about long-term safety. Some BACE1 inhibitors failed in trials due to cognitive worsening or side effects, raising questions about the optimal timing and selectivity of BACE1-targeting therapies. Despite these hurdles, antibodies remain attractive due to their tunable design and potential for peripheral targeting to modulate Aβ precursors.
Beyond therapeutics, BACE1 antibodies serve as vital tools in studying protease function, Aβ biology, and AD mechanisms. Ongoing efforts aim to engineer bispecific antibodies or optimize delivery methods to enhance efficacy while preserving physiological roles of BACE1 in synaptic plasticity and myelination.
×
